GENZ Stock Quote - stock news and information

GENZYME

(NSDQ: GENZ)Add to My Watchlist

Detailed Quote

News

Last Price	54.87 ( 4:30 PM EST)
Change (%)	+0.38 (+0.70%)
Volume	2,267,418
Open	55.02
Previous Close	54.49
Day High	55.47
Day Low	54.27
Bid	54.85 x 100
Ask	54.86 x 3600

Intraday

3 Month

6 Month

1 Year

Average Volume	3,316,950
Shares Outstanding	265.38M
Market Cap	14.6B
Year High	73.75
Year Low	47.09
Earnings Per Share	1.75
P/E Ratio	31.4
Dividend	N/A
Yield	N/A

Symbol	Last	Change (%)
AMGN	57.21	-0.25 (-0.44%)
GILD	46.30	+0.21 (+0.46%)
CELG	55.50	+0.73 (+1.33%)
CMXHF	28.00	+1.30 (+4.87%)
BIIB	54.09	+1.25 (+2.37%)
SHPGF	19.30	+0.10 (+0.52%)
SHPGY	58.49	+0.80 (+1.39%)
LIFE	47.82	+0.40 (+0.84%)

Tue, Jan 12, 2010
	Genzyme Revenue Down on Manufacturing Woes BOSTON (Reuters) - Genzyme Corp GENZ said on Tuesday that its fourth-quarter revenue fell as manufacturing problems caused a shortage of two key drugs.The Cambridge, Massachusetts-based biotech company released the unaudited figures at the J.P. Morgan healthcare conference.Total fourth-quarter revenue fell to $1.08 billion, down from $1.17 billion in the... - Reuters articles \| B...
Sun, Dec 13, 2009
	Genzyme Lab Recognized for Quality. Yes, Really. Genzyme GENZ investors might be forgiven for doing a double-take last week when they saw that a Genzyme laboratory was recognized for quality. After all, the words "Genzyme" and "quality" aren't often seen in close quarters these days, not unless the sentence also includes words like "abysmal" or "fiasco."... - BNET.com
Mon, Nov 30, 2009
	Genzyme's Termeer Sells $10M in Stock Despite Company's Woes No matter how badly Genzyme GENZ performs, CEO Henri Termeer just seems to fall ass-backwards into money. On Nov. 23 he sold $10 million in stock at $50.47 a share after exercising 200,000 options at $26.50 per share. by Jim Edwards - BNET.com
Mon, Nov 23, 2009
	Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next? Just when you thought it couldn't get any worse for Genzyme, a disappointing Phase II/III trial means the end for the firm's next-generation kidney drug. What could possibly happen next? by Trista Morrison - BNET.com
Thu, Nov 19, 2009
	Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet Henri Termeer, the CEO of disaster-prone Genzyme GENZ, was given $50.8 million in compensation for the last three years, according to the company's filings with the SEC (see page 24). He earns about $14 million a year for running a company that has about $4 billion in sales. By contrast,... - BNET.com
More Featured Content

Today
	Genzyme mentioned cautiously at Summer Street See the rest of the story here. Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself. - theflyonthewall.com
	Genzyme (GENZ) 2/9/10 PriceWatch Alert Bullish Price Movement Genzyme (NASDAQ: GENZ) closed yesterday at $54.49. So far the stock has hit a 52-week low of $47.09 and 52-week high of $73.75. Genzyme stock has been showing support around 53.38 and resistance in the 56.22 range. Technical indicators for the stock are Bullish and S&P gives GENZ a neutral 3 STAR ...(Click the story link or go to http://www.marketintelligencecenter.com for the full story) - MarketIntelligenceCe...
	Targeted Genetics receives milestone payments from Genzyme See the rest of the story here. Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself. - theflyonthewall.com
Mon, Feb 08, 2010
	On The Fly: Analysts Upgrade Summary See the rest of the story here. Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself. - theflyonthewall.com
	Goldman Sachs Removed Genzyme (GENZ) from Conviction Sell List, Adds St. Jude (STJ) Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5315776 for the full story. - StreetInsider
More News

Thu, Feb 04, 2010
	Critical Alerts for Intel, MetLife, Genzyme, AOL, and Ctrip.com Released by Seven Summits Research - PR Newswire
Wed, Feb 03, 2010
	Scott Canute Joins Genzyme to Head Manufacturing and Corporate Operations - Business Wire
Fri, Jan 29, 2010
	Genzyme Strengthens Role of Board’s Lead Independent Director - Business Wire
Thu, Jan 28, 2010
	Genzyme Adopts New Incentive Compensation Plans for Senior Executives - Business Wire
Thu, Jan 21, 2010
	Genzyme’s Lumizyme BLA Receives Six-Month FDA Review - Business Wire
More Press Releases

Mon, Feb 08, 2010
	Analyst upgrades, downgrades and initiations: CME, AZO, XOM, DNB, GENZ BloggingStocks: Analyst upgrades: Jefferies upgraded CME Group (CME) to Buy from Hold and has a $330 target on the stock. The firm believes increased regulatory concerns have created a buying opportunity and notes that CME Group's fundamentals are ... Read more - BloggingStocks
Wed, Feb 03, 2010
	RxNews Recap for Wednesday 02-03-10 - Biotech and Health C...
	Analyst Upgrades and Downgrades UBS, UPS, NWSA, WMT, KFT, MCD, CS, SCHW… Acme Packet (APKT, news: 13.42 +25.77%) upgraded to Neutral from Underweight at Piper Jaffray… Advanced Semi (ASX, news: 4.09 +5.41%) upgraded to Hold, $26 target, at Citi… Anglo American (AAUKY, news: 0.00 N/A) upgraded to Buy at UBS… Animal Health (AHII, news: 1.95 +5.98%) upgraded to Overweight from Neutral, $3 target, at Piper Jaffray… ArvinMeritor (ARM, news: 11.00 +3.29%) [...] - CEOWorld
	Housing And Biotech Stocks Rally: SPX, Nasdaq, DHI, MDC, TOL, PHM, CELG, GENZ, OSIP, CEPH, XNPT, CTRP, SOLR, NETL, CSCO, V, BRCM, YUM This morning, pending home sales numbers came in better than expected. In addition, DHI reported its first profittable quarter in 3 years! Housing stocks were very strong: DHI +10.92%, MDC +7.73%, TOL +3.59%, PHM +7.48%. Biotechs also had a good day with the BTK breaking above 1000, yet another all-time high: CELG +1.39%, GENZ +2.71%, [...] - Wang's Happy Trading
Fri, Jan 29, 2010
	RxNews Recap for Friday 01-29-10 - Biotech and Health C...
More Blogs

Thu, Oct 01, 2009
	October 1, 2009 - Today's Industrial Market News from Industrialinfo.com Companies featured in this segment: Genzyme Corporation (NASDAQ:GENZ), PetroChina Company Limited (NYSE:PTR), Cameco Corporation (NYSE:CCJ), Scottish and Southern Energy plc (OTC:SSEZY), Centrica plc (OTC:CPYYY), E.ON AG (OTC:EONGY), RWE AG (OTC:RWEOY) - Industrial Info Dail...
Mon, Aug 17, 2009
	August 17, 2009 - Today's Industrial Market News from Industrialinfo.com Companies featured in this segment: FirstEnergy Corporation (NYSE:FE), Exxon Mobil Corporation (NYSE:XOM), BP plc (NYSE:BP), Siemen AG (NYSE:SI), Chevron Corporation (Chevron) (NYSE:CVX), Royal Dutch Shell plc (NYSE:RDS.A), InterOil Corporation USA (NYSE:IOC), GlaxoSmithKline plc (NYSE:GSK), Pfizer Incorporated (NYSE:PFE), Novartis AG (NYSE:NVS), Eli Lilly & Company (NYSE:LLY), AstraZeneca plc (NYSE:AZN), Wyeth (NYSE:WYE), Genzyme Corporation (NASDAQ:GENZ), Merck & Company, Incorporated (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Santos Limited (OTC:STOSY), Petronet LNG Limited (BSE:532522) - Industrial Info Dail...
Wed, Jul 29, 2009
	Dorsey Wright's Podcast 193 - Portfolio Management Ideas and Strategies Tom Dorsey and Tammy DeRosier - Portfolio Management Ideas and Strategies - Dorsey Wright
Fri, May 15, 2009
	May 15, 2009 - Today's Industrial Market News from Industrialinfo.com Companies featured in this segment: Genzyme (NASDAQ:GENZ), Eli Lilly & Company (NYSE:LLY), NiSource Incorporated (NYSE:NI), General Electric (NYSE:GE), Siemens AG (NYSE:SI), The Dow Chemical Company (NYSE:DOW), Progress Energy’s (NYSE:PGN), Covanta Holding Corporation (NYSE:CVA), Sumitomo Chemical Company Limited (TYO:4005), Steel Authority of India Limited (BSE:500113), Endesa (MCE:ELE), and Saudi Basic Industries Corporation (SAU:2010) - Industrial Info Dail...
Tue, May 12, 2009
	May 12, 2009 - Today's Industrial Market News from Industrialinfo.com Companies featured in this segment: General Motors Corporation (NYSE:GM), Northfield Laboratories (NASDAQ:NFLD), Mitsui and Company Limited (NASDAQ:MITSY), Alkermes Incorporated (NASDAQ:ALKS), Shire plc (NASDAQ:SHPGY), ImmunoGen Incorporated (NASDAQ:IMGN), Schering-Plough (NYSE:SGP), BioMed Realty Trust Incorporated (NYSE:BMR), Amgen (NASDAQ:AMGN), Genzyme (NASDAQ:GENZ), Murphy Oil Corporation (NYSE:MUR), Centrica plc (OTC:CPYYY), Electric Power Development Company Limited (TYO:9513), and Electricite de France SA (EPA:EDF) - Industrial Info Dail...
More Podcasts

Wed, Feb 17, 10		Q4 2009 Earnings Archive for GENZ
Wed, Nov 18, 09		Special Conference Lazard Capital Markets 6th Annual Healthcare Conference Archive for GENZ
Tue, Nov 17, 09		Business News Genzyme/Isis Investor Event at AHA Archive for GENZ
Wed, Oct 21, 09		Q3 2009 Earnings Archive for GENZ
Wed, Jul 22, 09		Q2 2009 Earnings Archive for GENZ

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Real Time Stock News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs

MoneyWatch.com

About CBS MoneyWatch.com

MoneyWatch.com is the premier destination for smart, practical personal finance advice about your retirement, investing, savings, career and real estate. A joint effort between the news powerhouse CBS and the business experts at BNET, MoneyWatch.com is the place to go for personal financial insight you can trust.

Meet the CBS MoneyWatch.com Team

Feeds

Site Help & Feedback

Beta - Give us your feedback

About CBS MoneyWatch.com

Feeds

Site Help & Feedback

Your Work Four Secrets to Liking Your Work

Four Secrets to Liking Your Work

Your Industry Insights into your industry

Smart Business for Tough Times

Your Money Be Smarter, Look Younger, Perform Better, and Keep Your Job

Be Smarter, Look Younger, Perform Better, and Keep Your Job